In the second interview of this series, Ben Creelan, MD , Associate Member at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment. Targeted Oncology™: What have you learned about tumor-infiltrating lymphocytes (TILs) in melanoma? Ben Creelan, MD: I was fortunate to go to ESMO [European Society for Medical Oncology Congress 2022] this year where John Haanen [MD, PhD] was presenting data from a randomized open-label phase 3 trial, where metastatic melanoma patients who had progressed on previous anti–PD-1 therapy were randomized to either our gold standard since 2011, ipilimumab, given at a standard dose every three weeks for four doses, or TIL cell therapy. It was actually quite surprising to me that there was a significant difference in progression-free survival and a trend in overall survival between the tw...